This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas Pharma, Inc.
Drug Names(s): Bixalomer, AMG223, ILY101, ASP1585
Description: ILY101 is a non-absorbed, metal-free polymer that binds phosphorus in the gastrointestinal tract, allowing for excretion of phosphorus. It is therefore anticipated to ameliorate hyperphosphatemia by reducing the absorption of phosphorus from the gastrointestinal tract. ILY101 is designed to address the main compliance challenges of currently available phosphate binder therapies, including pill burden, efficacy and tolerability.
Deal Structure: In April 2006, Ilypsa and Astellas Pharma entered into a license agreement that gives Astellas exclusive rights to develop and market ILY101 in Japan. Under this agreement, Astellas will pay Ilypsa a total of $92 million, including an upfront payment of $22 million, as well as royalties in the mid-teen range on future sales of the drug in Japan.
In July 2007, Amgen completed the acquisition of Ilypsa.
In February 2012, Astellas Pharma and Sanwa Kagaku Kenkyusho announced that they agreed to establish a strategic alliance for the pharmaceutical market for kidney diseases in Japan. Under this agreement, Astellas will distribute and both companies will co-promote the hyperphosphatemia treatment bixalomer (generic name, development code: ASP1585), whose market authorization application Astellas submitted to the Ministry of Health, Labour and Welfare in Japan.
Partners: Amgen, Inc. Sanwa Kagaku Kenkyusho Co., Ltd.
Additional information available to subscribers only: